Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines

Carcinogenesis

Volumn 28, Issue 2, 2007, Pages 378-389

  Niture, Suryakant K ^a   Velu, Chinavenmani S ^a   Smith, Quentin R ^a   Bhat, G Jayarama ^a   Srivenugopal, Kalkunte S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 5 OXOPROLINASE; ACETYLCYSTEINE; ACIVICIN; AMIDASE; ANTIOXIDANT; CURCUMIN; CYSTEINE; FENRETINIDE; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; HERBACEOUS AGENT; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NATURAL PRODUCT; OLTIPRAZ; PRODRUG; RESVERATROL; SILYMARIN; SULFORAPHANE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CELL STRAIN HCT116; CELL STRAIN HT29; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; STEADY STATE;

ACETYLCYSTEINE; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BASE SEQUENCE; BIOLOGICAL PRODUCTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CURCUMIN; CYSTEINE; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENRETINIDE; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LYMPHOCYTES; PRODRUGS; PYRAZINES; RNA, MESSENGER; SILYMARIN; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33847290910     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl155     Document Type: Article

References (76)

1. Mitra,S. and Kaina,B. (1993) Regulation of repair of alkylation damage in mammalian genomes. Prog. Nucleic Acid Res. Mol. Biol., 44, 109-142.
2. Goldman,R. and Shields,P.G. (2003) Food mutagens. J. Nutr., 133, (Suppl. 3), 965S-973S.
3. Bailey,G.S. and Williams,D.E. (1994) Potential mechanisms for food-related carcinogens and anti-carcinogens. Food Tech., 47, 105-118.
4. Hecht,S.S. (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol., 11, 559-603.
5. Wang,M., Cheng,G., Sturla,S.J., Shi,Y., McIntee,E.J., Villalta,P.W., Upadhyaya,P. and Hecht,S.S. (2003) Identification of adducts formed by pyridyloxobutylation of deoxyguanosine and DNA by 4-(acetoxymethylnitrosamino)- 1-(3-pyridyl)-1-butanone, a chemically activated form of tobacco specific carcinogens. Chem. Res. Toxicol., 16, 616-626.
6. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50, 6119-6129.
7. Singer,B. (1982) Correlations between sites of chemical modification of DNA, repair, and carcinogenesis. Princess Takamatsu Symp., 12, 117-137.
8. 6-methylguanine. Mutagenesis, 17, 483-487.
9. Rydberg,B. and Lindahl,T. (1982) Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. EMBO J., 1, 211-216.
10. 6-methylguanine in DNA. Cancer Res., 57, 366-369.
11. 4-ethylthymine in human liver and peripheral blood leukocyte DNA. Carcinogenesis, 16, 1277-1280.
12. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis, 24, 625-635.
13. 6-alkylguanine by alkyltransferases. Mutat. Res., 462, 83-100.
14. Gerson,S.L. (2004) MGMT: Its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer, 4, 296-307.
15. 6-benzylguanine and its role in chemotherapy. Clin. Cancer. Res., 3, 837-847.
16. Sekiguchi,M. and Sakumi,K. (1997) Roles of DNA repair methyltransferase in mutagenesis and carcinogenesis. Jpn. J. Hum. Genet., 42, 389-399.
17. Sekiguchi,M. and Sanada,M. (1999) Alkylation carcinogenesis in mice with altered levels of DNA repair methyltransferase. Prog. Exp. Tumor Res., 35, 25-36.
18. 6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. Oncogene, 20, 5258-5263
19. Liu,L., Qin,X. and Gerson,S.L. (1999) Reduced lung tumorigenesis in human methylguanine DNA - methyltransferase transgenic mice achieved by expression of transgene within the target cell. Carcinogenesis, 20, 279-284.
20. 6-methylguanine-DNA methyltransferase. Proc. Natl Acad. Sci. USA, 98, 12566-12571.
21. 6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. Int. J. Mol. Med., 11, 65-99.
22. 6-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer, 92, 2760-2768.
23. 6-methylguanine-DNA methyltransferase: Promoter hypermethylation, associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol. Carcinog., 36, 23-31.
24. Lees,N.P., Harrison,K.L., Hall,C.N., Margison,G.P. and Povey,A.C. (2004) Reduced MGMT activity in human colorectal adenomas is associated with K-ras GC→AT transition mutations in a population exposed to methylating agents. Carcinogenesis, 25, 1243-1247.
25. Zaidi,N.H., Pretlow,T.P., O'Riordan,M.A., Dumenco,L.L., Allay,E. and Gerson,S.L. (1995) Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis, 16, 451-456.
26. 6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene, 18, 3783-3787.
27. Shen,J., Terry,M.B., Gammon,M.D., Gaudet,M.M., Teitelbaum,S.L., Eng,S.M., Sagiv,S.K., Neugut,A.I. and Santella,R.M. (2005) MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk. Carcinogenesis, 26, 2131-2137.
28. 6-alkylguanine-DNA alkyltransferase gene polymorphisms and the risk of primary lung cancer. Mol. Carcinog., 45, 239-249.
29. 6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke. Cancer Epidemiol. Biomarkers Prev., 13, 320-323.
30. 6-methylguanine DNA adducts associated with occupational nitrosamine exposure. Carcinogenesis, 21, 29-33.
31. 6-methylguanine DNA methyltransferase and breast cancer risk. Pharmacogenet. Genomics, 16, 469-474.
32. Inoue,R., Isono,M., Abe,M., Abe,T. and Kobayashi,H. (2003) A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma. Neurol. Res., 25, 875-879.
33. 6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum. Gene Ther., 15, 758-769.
34. Matesich,S.M. and Shapiro,C.L. (2003) Second cancers after breast cancer treatment. Semin Oncol., 30, 740-748.
35. 6-methylguanine-DNA methyltransferase levels in tissues of methionine-cysteine deficient subadult and adult mice. Comp. Biochem. Physiol., 91C, 603-606.
36. 6-methylguanine-DNA methyltransferase by methionine in human tumor cells. Br. J. Cancer, 75, 779-788.
37. Williamson,J.M. and Meister,A. (1981) Stimulation of hepatic glutathione formation by administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxo-L-prolinase substrate. Proc. Natl Acad. Sci. USA, 78, 936-939.
38. Meister,A. (1988) Novel drugs that affect glutathione metabolism. In: Mechanisms of Drug Resistance in Neoplastic Cells, Tew, K. Ed., Academic Press, New York, pp. 100-125.
39. De Flora,S., Cesarone,C.F., Balansky,R.M. et al. (1995) Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background. J. Cell Biochem. Suppl., 22, 33-41.
40. Dick,R.A. and Kensler,T.W. (2002) Chemoprotective potential of phase 2 enzyme inducers. Expert. Rev. Anticancer Ther., 2, 581-592.
41. 6-alkylguanine-DNA alkyltransferase in human brain tumor cells. Cancer Res., 60, 282-287.
42. Colovai,A.I., Stoica,A., Cinca,S.A., Marin,M., Gruia,M., Condrea,I., Petrescu,D. and Dutu,R. (1992) Glutathione S-transferase activity in human breast tumors. Neoplasma, 39, 249-254.
43. 6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds. Oncol Rep., 14, 1275-1280.
44. Gaitonde,M.K. (1967) A spectrophotometric method for the determination of cysteine in the presence of other naturally occurring amino acids. Biochem. J., 104, 627-633.
45. Srivenugopal,K.S. and Ali-Osman,F. (1997) Activity and distribution of the cysteine prodrug activating enzyme, 5-oxo-L-prolinase, in human normal and tumor tissues. Cancer Lett., 117, 105-111.
46. Ferguson,L.R., Zhu,S.T. and Harris,P.J. (2005) Antioxidant and antigenotoxic effects of plant cell wall hydroxycinnamic acids in cultured HT-29 cells. Mol. Nutr. Food Res., 49, 585-593.
47. Piton,A., Le Ferrec,E., Langouet,S., Rauch,C., Petit,E., Le Goff,F., Guillouzo,A. and Morel,F. (2005) Oltipraz regulates different categories of genes relevant to chemoprevention in human hepatocytes. Carcinogenesis, 26, 343-351.
48. Sharma,R., Yang,Y., Sharma,A., Awasthi,S. and Awasthi,Y. (2004) Antioxidant role of glutathione S-transferases: Protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid. Redox. Signal, 6, 289-300.
49. Stipanuk,M.H., Dominy,J.E.Jr, Lee,J.I. and Coloso,R.M. (2006) Mammalian cysteine metabolism: New insights into regulation of cysteine metabolism. J. Nutr., 136, 1652S-1659S.
50. Pompella,A., De Tata,V., Paolicchi,A. and Zunino,F. (2006) Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem. Pharmacol., 71, 231-238.
51. 6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis, 7, 745-749.
52. Frosina,G. and Abbondandolo,A. (1985) The current evidence for an adaptive response to alkylating agents in mammalian cells, with special reference to experiments with in vitro cell cultures. Mutat. Res., 154, 85-100.
53. Lindahl,T., Sedgwick,B., Sekiguchi,M. and Nakabeppu,Y. (1988) Regulation and expression of the adaptive response to alkylating agents. Annu. Rev. Biochem, 57, 133-157.
54. 6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem. Biophys. Res. Commun., 337, 1176-1184.
55. Barret,J.-M., Calsou,P. and Salles,B. (1995) Deficient nucleotide excision repair activity in protein extracts from normal human lymphocytes. Carcinogenesis, 16, 1611-1616.
56. Losa,G.A. (2003) Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur. J. Clin. Invest., 33, 818-823.
57. Gordon,G.B., Prochaska,H.J. and Yang,L.Y.-S. (1991) Induction of NAD(P)H: quinine reductase in human peripheral blood lymphocytes. Carcinogenesis, 12, 2393-2396.
58. Robert,J.C. and Francetic,D.J. (1991) Time course for elevation of GSH in numerous organs of tumor bearing mice given L-cysteine prodrug, Ribocys. Toxicol. Lett., 59, 245-251.
59. Nishina,H., Ohta,J. and Ubuka,T. (1987) Effect of L-2-oxothiazolidine-4-carboxylate administration on glutathione and cysteine concentrations in guinea pig liver and kidney. Physiol. Chem. Phys. Med. NMR., 19, 9-13.
60. Hazelton,G.A., Hjelle,J.J. and Klassen,C.D. (1986) Effects of cysteine prodrugs on acetaminophen-induced hepatotoxicity. J. Pharmacol. Exp. Ther., 237, 341-349.
61. Brodeur,J. and Goyal,R. (1987) Effect of a cysteine prodrug, oxothiazolidine-4-carboxylate on the metabolism and toxicity of bromobenzene: An acute study. Can. J. Pharmac., 65, 816-822.
62. Russo,A., DeGraff,W., Friedman,N. and Mitchell,J.B. (1986) Selective modulation of glutathione levels in human normal versus tumor cells and subsequent response to chemotherapy drugs. Cancer Res., 46, 2845-2848.
63. Taylor,C.G., Bauman,P.F., Sikorski,B. and Bray,T.M. (1992) Elevation of lung glutathione by oral supplementation of L-2-oxothiazolidine-4-carboxylate protects against oxygen toxicity in protein-energy malnourished rats. FASEB J., 6, 3101-3107.
64. Barditch-Crovo,P. Noe,D., Lederman,M., Borum,P., Rowe,W.B., Goldberg,D. and Lieman,P. (1998) A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus. J. clin. Pharmacol., 38, 357-363.
65. Porta,P., Aebi,S., Summer,K. and Lauterburg,B.H. (1991) L-2-oxothiazolidine-4-carboxylate cysteine prodrug: Pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J. Pharmacol. Ther., 257, 331-334.
66. Cudkowicz,M.E., Sexton,P.M., Ellis,T., Hayden,D.L., Gwilt,P.R., Whalen,J. and Brown,R.H. (1999) The pharmacokinetics and pharmacodynamics of procysteine in amyotrophic lateral sclerosis. Neurology, 52, 1492-1494.
67. Kwon,Y.H. and Stipanuk,N.H. (2001) Cysteine regulates expression of cysteine dioxygenase and gamma-glutamylcysteine synthetase in cultured hepatocytes. Am. J. Physiol. Endocrinol. Metab., 280, E804-815.
68. Lantum,H.B., Iyer,R.A. and Anders,M.W. (2004) Acivicin-induced alterations in renal and hepatic glutathione concentrations and in γ-glutamyltransferase activities. Biochem. Pharmacol., 67, 1421-1426.
69. Rainone,F. (2005) Milk thistle. Amer. Fam. Physician., 72, 1285-1288.
70. Singh,R.P. and Agarwal,R. (2005) Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur. J. Cancer, 41, 1969-1979.
71. Kohno,H., Tanaka,T., Kawabata,K., Hirose,Y., Sugie,S., Tsuda,H. and Mori,H. (2002) Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int. J. Cancer, 101, 461-468.
72. Sharma,R.A., Gescher,A.J. and Steward,W.P. (2005) Curcumin: The story so far. Eur. J. Cancer, 41, 1955-1968.
73. Maheshwari,R.K., Singh,A.K., Gaddipati,J. and Srimal,R.C. (2006) Multiple biological activities of curcumin: A short review. Life Sci., 78, 2081-2087.
74. Kim,H.J. and Lotan,R. (2004) Identification of retinoid-modulated proteins in squamous carcinoma cells using high-throughput immunoblotting. Cancer Res., 64, 2439-2448.
75. Kang,K.W., Lee,S.J. and Kim,S.G. (2005) Molecular mechanism of Nrf2 activation by oxidative stress. Antioxid. Redox. Signal., 7, 1664-1673.
76. 6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res., 19, 6163-6167.